Rivastigmine in the treatment of Alzheimer's disease: an update
نویسندگان
چکیده
منابع مشابه
Rivastigmine in the treatment of Alzheimer’s disease: an update
Alzheimer's disease is the most common form of dementia in industrialized countries. In the European Union, about 54% of dementia cases are believed to be due to Alzheimer's disease. The condition is an age-related neurodegenerative disorder characterized by multiple cognitive deficiencies, including loss of memory, judgment, and comprehension. These manifestations are accompanied by behavioral...
متن کاملGlucose Role in Treatment of Alzheimers’ Disease
1. Dong H, Csernansky JG (2009) Effects of Stress and Stress Hormones on Amyloidβ Protein and Plaque Deposition. J Alzheimers Dis 18: 459-469. 2. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, et al. (2006) Plasma cortisol and progression of dementia in subjects with Alzheimer‐ type dementia. Am J Psychiatry 163: 2164-2169. 3. Swaab DF, Raadsheer FC, Endert E, Hofman MA, Kamphorst W, et al. ...
متن کاملUpdate on rivastigmine.
BACKGROUND Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes. Butyrylcholinesterase in-creases as Alzheimer disease progresses, so its inhibition may become more important as the disease worsens. Metabolism of rivastigmine occurs at the synapse rather than at the liver and previous studies h...
متن کاملCadmium toxicity and treatment: An update
Cadmium poisoning has been reported from many parts of the world. It is one of the global health problems that affect many organs and in some cases it can cause deaths annually. Long-term exposure to cadmium through air, water, soil, and food leads to cancer and organ system toxicity such as skeletal, urinary, reproductive, cardiovascular, central and peripheral nervous, and respiratory systems...
متن کاملOnce-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
During the past decade, transdermal delivery systems (TDS) have become increasingly important for treating neurologic and psychiatric disorders. The rivastigmine patch was the first patch to be approved to treat Alzheimer's disease (AD). The 9.5 mg/24 h patch has equal efficacy to the capsules and reduces gastrointestinal adverse events, such as nausea and vomiting, by two-thirds. This treatmen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Interventions in Aging
سال: 2007
ISSN: 1176-9092
DOI: 10.2147/ciia.2007.2.1.17